CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases

Phase 1approvedCRT-402Positive

AI Analysis

Summary

CREATE Medicines received Australian HREC approval to initiate its first-in-human Phase 1/2 clinical trial of CRT-402, an in vivo CAR-T candidate, in patients with systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathies.

Clinical Trial Data

Phase

Phase 1/2

Outcome Details

Australian HREC approval to initiate first-in-human Phase 1/2 clinical trial

Importance:6/10

Sentiment:

0.70

CAR-T therapyin vivoautoimmune diseasesystemic lupus erythematosusregulatory approvalclinical trial initiation

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on July 30, 2026 11:00 AM

Read Original